OTC$EVFM
Evofem Biosciences Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Evofem Biosciences reported financial results for Q2 2020 and provided a corporate update.
Evofem Biosciences reported a net loss of $52.7 million for the second quarter of 2020. The company is preparing for the commercial launch of Phexxi in September 2020 and is on track to initiate a Phase 3 trial of EVO100 in Q4 2020. They ended the quarter with $123.6 million in unrestricted cash and short-term investments.
- Received FDA approval for Phexxi for prevention of pregnancy.
- Strengthened balance sheet with $136 million in gross proceeds from financing transactions.
- Phexxi was granted new classification as the first and only 'Vaginal pH Modulator' by Medi-Span and First Databank.
- Met with major commercial payers and garnered early formulary inclusion of Phexxi at $0 copay from several regional insurers.
Headline financials
Revenue & EPS history
Evofem Biosciences · Revenue · Quarterly
$899K
Revenue by segment
Evofem Biosciences · $899K total across 1 segment · Q1 2026
- Product Sales$899K—100.0%
Forward guidance
Evofem Biosciences provided financial guidance for fiscal year 2020 and expects cash burn of approximately $36 to $38 million in the third quarter and approximately $42 to $44 million in the fourth quarter of 2020.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
-4.2%
Avg return
Earnings day
-6.2%
Avg return
5 days after
-6.7%
Avg return
30 days after
29%
13 / 45 earnings
Positive
+32.4%
Q4 2023
Best reaction
-36.7%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | -4.5% | +19.7% | |
| Q3 2025 | +11.1% | +11.1% | +33.3% | |
| Q2 2025 | +11.1% | +11.1% | +77.8% | |
| Q1 2025 | +12.5% | +12.5% | +25.0% | |
| Q3 2024 | -16.5% | -16.7% | -16.7% | |
| Q2 2024 | +6.4% | +11.1% | +0.0% | |
| Q1 2024 | -15.3% | -12.5% | -41.7% | |
| Q4 2023 | +32.4% | +11.1% | -5.6% | |
| Q3 2023 | +0.0% | +0.0% | +21.4% | |
| Q2 2023 | -13.3% | -13.0% | -51.1% | |
| Q1 2023 | -9.5% | -4.8% | -61.9% | |
| Q4 2024 | +0.0% | -13.6% | -13.6% | |
| Q3 2022 | -19.2% | -4.1% | -34.2% | |
| Q4 2022 | -19.2% | -4.1% | -34.2% | |
| Q2 2022 | +8.4% | -28.3% | -63.2% | |
| Q1 2022 | -18.2% | -20.7% | -51.5% | |
| Q4 2021 | -17.4% | -26.5% | -44.3% | |
| Q3 2021 | -16.3% | -31.3% | -43.3% | |
| Q2 2021 | -10.0% | -20.6% | -2.7% | |
| Q1 2021 | +16.8% | +8.1% | -14.5% | |
| Q4 2020 | -36.7% | -36.9% | -43.9% | |
| Q3 2020 | -3.7% | -10.6% | -11.8% | |
| Q2 2020 | -5.0% | -8.4% | +11.9% | |
| Q1 2020 | -2.0% | -0.4% | -35.2% | |
| Q4 2019 | -19.8% | -21.3% | +1.0% | |
| Q3 2019 | +0.8% | +5.1% | +34.9% | |
| Q2 2019 | -10.7% | -6.8% | -1.3% | |
| Q1 2019 | +31.8% | +59.6% | +49.9% | |
| Q4 2018 | -20.7% | -21.4% | -15.7% | |
| Q3 2018 | -9.8% | -12.1% | -8.8% | |
| Q2 2018 | -5.1% | -7.8% | +87.1% | |
| Q1 2018 | -11.4% | -15.6% | -46.9% | |
| Q4 2017 | -3.5% | -3.0% | -5.3% | |
| Q3 2017 | -3.2% | +2.4% | +13.7% | |
| Q2 2017 | -17.4% | -23.0% | -27.2% | |
| Q1 2017 | +2.2% | +8.6% | -0.5% | |
| Q4 2016 | -2.1% | -2.1% | +31.5% | |
| Q3 2016 | +0.9% | +0.9% | -1.7% | |
| Q2 2016 | -11.9% | -11.8% | +8.9% | |
| Q1 2016 | -6.9% | — | — | |
| Q4 2015 | +4.8% | — | — | |
| Q3 2015 | -6.4% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | +6.5% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro